AI Drug Discovery for Pharma and Biotech

Drug discovery

116

papers

On emerging therapies

Overview

Peritoneal inclusion cysts (PICs) are non-neoplastic, reactive cystic lesions caused by mesothelial proliferation following peritoneal injury or inflammation. They primarily present in premenopausal women with pelvic pain, often mimicking ovarian cysts or malignancies. Diagnosis relies on imaging (ultrasound, CT, or MRI) showing fluid-filled septations surrounding a normal ovary. Management prioritizes symptom relief due to high recurrence rates (~50%) despite surgical resection [1][2][6][16].

Population

  • Primarily premenopausal women (82.5% of cases), but also affects men (17.5%) [2][6].

  • Risk factors: Prior abdominal/pelvic surgery, endometriosis, pelvic inflammatory disease, or trauma [1][12][17].

Burden

  • High recurrence rates (30–50% post-surgery) [6][11][12].

  • Chronic pelvic pain, infertility, and complications like hydronephrosis [1][7][12].

  • Frequent imaging/surgical interventions increase healthcare utilization [6][10][13].

Therapies

  • Observation: For asymptomatic cases [16].

  • Hormonal therapy: Oral contraceptives to reduce ovarian fluid production [8][16].

  • Minimally invasive procedures: Laparoscopic cyst excision (reduced morbidity vs. laparotomy) [3][13] or sclerotherapy (ethanol/povidone-iodine) [8].

Categories: rare abdominal surgical diseases, rare neoplastic diseases

Research Papers

116 drug discovery papers about Peritoneal inclusion cyst. Recent publications:

116 drug discovery papers about Peritoneal inclusion cyst. Recent publications:

categories:

Small molecules

small molecules
2026-07-01 | Ayurvedic management of Peritoneal inclusion cyst: Clinical documentation of a single case

Abstract: Peritoneal Inclusion Cysts (PICs) are benign, reactive cystic lesions commonly occurring in women of reproductive age, often following pelvic surgery or chronic inflammation. They may present with pelvic pain, infertility, or be detected incidentally during imaging. The case of a 35-year-old woman with secondary infertility, history of hysteroscopic septum resection and polypectomy, diagnosed with a PIC measuring 62 mm × 57 mm × 38 mm is being presented here. The patient was advised surgical management by the conventional physician; however, the patient opted for Ayurvedic treatment. A regimen comprising of oral medications including Gandharvahastadi kashaya, Dhanwantara taila, Shigru guggulu , and local application of Lepa (~anointment) of Shigru patra ( Moringa oleifera Lam.) was administered for one month. Follow-up ultrasonography revealed complete resolution of the cyst, with sustained symptomatic relief and no recurrence at seven months. The present case demonstrated complete radiological resolution of a PIC following Ayurvedic intervention without surgery, suggesting a potential conservative management option in selected stable cases. Further clinical studies are needed to establish its efficacy and reproducibility in larger population.

Open article ↗



2026-01-12 | Cytoreductive surgery and HIPEC for multicystic peritoneal mesothelioma: therapeutic approach in a rare benign neoplasm.

Multicystic peritoneal mesothelioma (MCPM) is an uncommon tumor of mesothelial origin, characterized by multiple interconnected cystic spaces and uncertain biological behavior. Although traditionally considered benign, its tendency to recur and occasionally spread within the peritoneal cavity challenges this perception. We describe a 32-year-old woman who experienced gradually worsening pelvic pain and a constant feeling of pressure, which intensified after childbirth. Imaging revealed a large multilocular cystic mass occupying the pelvis. At laparotomy, a gelatinous, multilocular lesion was found adherent to the pelvic peritoneum, uterus, ovaries, and rectosigmoid colon. Complete cytoreductive surgery was performed, including pelvic peritonectomy, omentectomy, appendectomy, and resection of the affected serosa, followed by closed-abdomen hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin (300 mg/m2, 42°C, 90 min). Histopathology confirmed benign multicystic mesothelioma with a mesothelial immunophenotype. The patient recovered well and remains disease-free at 6 months. MCPM requires complete cytoreduction, and HIPEC may help achieve lasting disease control.

Open article ↗



2025-10-28 | Peritoneal inclusion cyst presenting as a rectocele after sacrohysteropexy: A case report.

Peritoneal inclusion cysts (PICs) are mesothelial-lined cystic lesions that usually arise in reproductive-aged women after prior pelvic or abdominal surgery. Their diagnosis is often difficult, as they can mimic ovarian tumors or malignant pelvic masses. There are very few reports of PICs following pelvic reconstructive surgery. This report concerns the case of a 40-year-old nulliparous woman with a history of open sacrohysteropexy for stage IV pelvic organ prolapse who presented with progressive left lower quadrant pain and a vaginal bulge. Imaging revealed a large multilocular retroperitoneal cyst enveloping the left ovary and extending into the rectovaginal septum. Tumor markers were within normal limits. Due to the cyst's proximity to the bowel, ureter, and major vessels, and to avoid mesh erosion, a vaginal surgical approach was selected. Approximately 300 mL of serous fluid was drained, the cyst wall was excised under rectal guidance, and marsupialization was performed to the vaginal mucosa. Histopathology confirmed a benign mesothelial-lined cyst. At one-year follow-up, the patient remained asymptomatic with no recurrence evident on imaging. This is seemingly the first reported case of a retroperitoneal PIC following sacrohysteropexy. The case underscores the diagnostic challenges posed by PICs and highlights the role of individualized, minimally invasive management. Clinicians should maintain a high index of suspicion for PICs when evaluating postoperative pelvic or vaginal masses, particularly when imaging suggests a cystic lesion.

Open article ↗



2025-07-04 | Benign multicystic peritoneal mesothelioma: use of hyperthermic intraperitoneal chemotherapy (HIPEC).

Benign Multicystic Peritoneal Mesothelioma (BMPM) is a rare mesothelial neoplasm, first described in 1979, with an estimated incidence of 1-2 cases per million. It primarily affects women of reproductive age and has been associated with chronic inflammatory processes such as endometriosis or previous surgeries. Due to its clinical and radiological similarity to ovarian neoplasms, it is essential to include gynecological pathology in the differential diagnosis.

Open article ↗



2025-04-28 | Cisplatin + docetaxel improves survival over cisplatin + mitomycin C in hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a retrospective study based on propensity score matching.

Pseudomyxoma peritoneum (PMP) of appendiceal origin poses significant treatment challenges with hyperthermic intraperitoneal chemotherapy (HIPEC) regimens offering viable outcomes. This study aimed to compare the efficacy and safety profiles of two HIPEC regimens: cisplatin + docetaxel (CD) and cisplatin + mitomycin C (CM). PMP patients who underwent cytoreductive surgery (CRS) and HIPEC between January 2008 and December 2023 at our center were retrospectively analyzed. Patients were divided into CD and CM groups and matched for baseline characteristics using propensity score matching (PSM). Clinicopathological data, efficacy, and safety profiles were compared. Univariate and multivariate analyses identified independent prognostic factors, and subgroup analyses further compared the two regimens. After PSM, 104 patients met the inclusion criteria (52 in each group). The median overall survival (mOS) was significantly longer in the CD group (156.3 vs. 60.9 months, p = 0.018), with no significant differences in adverse event severity between groups. Multivariate analysis identified HIPEC regimen, completeness of cytoreduction (CC), and pathological type as independent prognostic factors. Subgroup analysis showed significant mOS benefit for the CD regimen in patients with peritoneal carcinomatosis index (PCI) ≥ 27, CC 2/3, high grade pathology, tumor markers ≥1 evaluated and BMI < 25 (all p < 0.005). Following CRS, the CD regimen offers superior survival benefits compared to the CM regimen for PMP patients. These findings highlight the potential of personalized HIPEC strategies to optimize outcomes for PMP treatment.

Open article ↗



antibodies
2026-05-28 | Simultaneous Occurrence of Well-Differentiated Papillary Mesothelial Tumor and Multicystic Mesothelioma

We report a rare case of simultaneous well-differentiated papillary mesothelial tumor (WDPMT) and multicystic mesothelioma. The concurrent occurrence of these entities is exceptionally uncommon and may pose challenges during surgical intervention. Both tumors are variants of epithelioid mesothelioma and are most frequently identified incidentally during surgical procedures. A 41-year-old patient was admitted for laparoscopic surgery due to a left adnexal mass. Ultrasound examination revealed a 5 cm lesion adjacent to the left ovary, exhibiting central vascularization. Intraoperatively, the mass appeared as a solid, soft, and nodular tumor. Frozen section analysis confirmed the diagnosis of WDPMT involving the left adnexa. Recognition of well-differentiated papillary mesothelial tumor and multicystic mesothelioma is critical for accurate differential diagnosis from malignant mesothelioma. Awareness of these entities informs appropriate surgical management and follow-up protocols.

Open article ↗



2026-02-10 | Incidental Adnexal Lesions: CT Diagnosis and Interreader Agreement.

Background The management of incidental adnexal lesions encountered at CT depends on the diagnosis, but little evidence supports CT diagnosis of most adnexal lesion types. Purpose To evaluate the interreader agreement and CT diagnosis of incidentally discovered adnexal lesions. Materials and Methods This institutional review board-approved, multi-institutional, multireader retrospective study conducted from January 1, 2022, to June 30, 2023, included patients who had malignant ovarian lesions with metastases (n = 8) and without metastases (n = 8), simple cysts (n = 6), dermoids (n = 9), hydrosalpinx (n = 5), benign cystadenomas and/or cystadenofibromas (n = 10), hemorrhagic cysts (n = 8), endometriomas (n = 6), ovarian fibromas (n = 5), leiomyomas (n = 5), and peritoneal inclusion cysts (n = 5) detected at CT. Nine members of the Society of Abdominal Radiology Uterine and Ovarian Cancer Disease-Focused Panel, blinded to the final diagnosis, independently reviewed the CT images and used the American College of Radiology white paper to determine the most likely diagnosis. A 2 × 2 factorial random-effects model was used to calculate the mean adjusted accuracy and disparity among the readers. Interreader agreement was calculated using a Gwet AC1 test. Results In total, 75 patients (mean age, 50 years ± 16 [SD]) were included. The mean adjusted accuracy and interreader agreement were highest for dermoids (99% and 0.97, respectively), malignant ovarian lesions with metastases (94% and 0.90), and simple cysts (86% and 0.64). The mean adjusted accuracy for all other lesion types was less than 72%, with fair to moderate interreader agreement. Overall, readers more accurately diagnosed malignant lesions (82%) than benign lesions (52%) (P < .001). Readers recorded a benign diagnosis when a malignant lesion was present 28% of the time (20 of 72) (P < .001) when there were no metastases. Conclusion Readers' mean adjusted accuracy was greatest for dermoids, malignant ovarian lesions with metastases, and simple cysts at CT, with substantial to almost perfect interreader agreement; all other lesions were challenging, and a substantial number of malignant ovarian lesions were misdiagnosed as benign. © RSNA, 2026.

Open article ↗



2025-07-03 | A large peritoneal inclusion cyst in a postmenopausal female without risk factors.

Peritoneal inclusion cysts (PICs) are rare, benign cystic lesions most often seen in females of reproductive age with a history of peritoneal injury. This case presents a 55-year-old postmenopausal female with no known risk factors who developed a large PIC, causing abdominal pain, fullness, and distention. Imaging, including CT and MRI, revealed a lobulated, fluid-filled mass in the left peritoneal cavity, initially suspected to be a lymphangioma. MRI confirmed the presence of a multilocular cyst with enhancing septa. Surgical exploration identified the cyst as a PIC involving the jejunal mesentery, with final pathology confirming the benign nature of the lesion. While PICs are typically associated with premenopausal females and peritoneal trauma, this case highlights their potential occurrence in postmenopausal age groups without prior insults. The ability to recognize characteristic imaging features-such as cystic lesions with enhancing septa on CT and MRI-can help differentiate PICs from other cystic abdominal masses, including lymphangiomas and neoplastic cystic masses.

Open article ↗



2025-04-12 | Multicystic peritoneal mesothelioma with floret-like multinucleated giant cells: A case report.

Multicystic peritoneal mesothelioma is an uncommon neoplasm characterized by multiple cysts adhering to the abdominal cavity. The symptoms are nonspecific, and their severity appears to be related to the size and location of the cysts. We report the case of a 55-year-old man with morbid obesity in whom a multiloculated mesenteric mass was incidentally discovered on abdominal ultrasound. Complementary imaging studies revealed a multicystic peritoneal tumour with a maximum diameter of 32cm, located in the pelvis and extending to the right hemiabdomen. Histologically, multiple cysts lined by mesothelial cells without atypia were observed, along with loose fibrous stroma containing numerous multinucleated floret-like giant cells. Based on the histopathological findings, the final diagnosis was multicystic peritoneal mesothelioma.

Open article ↗



2022-01-04 | A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial.

Platinum based chemotherapy is the treatment of choice for ovarian cancer patients with a platinum treatment free interval of >6 months. Niraparib is an oral poly (ADP-ribose) polymerase inhibitor approved as maintenance therapy after a response to platinum rechallenge, regardless of BRCA status. Atezolizumab is a humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1). A combination of poly (ADP-ribose) polymerase inhibitor and anti-PD-L1/programmed cell death protein 1 (PD-1) has shown synergy in preclinical models and promising clinical activity. To determine whether the addition of atezolizumab to carboplatin based chemotherapy and to subsequent maintenance with niraparib improves progression free survival compared with placebo in patients with recurrent disease and a platinum treatment free interval of >6 months. The Atezolizumab and NIraparib Treatment Association (ANITA) trial is a GEICO (Grupo Español de Investigación en Cáncer de Ovario) led phase III, randomized, double-blinded, multicenter European Network for Gynecological Oncological Trials (ENGOT) study. Patients will be randomized to arm A (control arm) consisting of platinum based chemotherapy (investigator's choice) plus a placebo of atezolizumab followed by maintenance niraparib plus a placebo of atezolizumab, or to arm B (experimental arm) consisting of platinum based chemotherapy (investigator's choice) plus atezolizumab followed by maintenance niraparib plus atezolizumab. Inclusion criteria are women aged over 18 years, diagnosed with relapsed high grade serous, endometrioid, or undifferentiated ovarian, fallopian tube, or primary peritoneal carcinoma. Patients are eligible if they received no more than two previous lines of chemotherapy, relapsed ≥6 months after the last platinum containing regimen, and have at least one measurable lesion according to the response evaluation criteria in solid tumors, version 1.1. The primary endpoint for this study is progression free survival. Approximately 414 patients will be recruited and randomized in a 1:1 ratio, with the aim of demonstrating a benefit in progression free survival for the experimental arm with a hazard ratio of O.7, using a two sided alpha of 0.05 and a power of 80%. The trial was launched in the fourth quarter of 2018 and is estimated to close in the second quarter of 2021. Mature results for progression free survival are expected to be presented by 2023. Clinicaltrials.gov NCT03598270.

Open article ↗



small molecules
2026-07-01 | Ayurvedic management of Peritoneal inclusion cyst: Clinical documentation of a single case

Abstract: Peritoneal Inclusion Cysts (PICs) are benign, reactive cystic lesions commonly occurring in women of reproductive age, often following pelvic surgery or chronic inflammation. They may present with pelvic pain, infertility, or be detected incidentally during imaging. The case of a 35-year-old woman with secondary infertility, history of hysteroscopic septum resection and polypectomy, diagnosed with a PIC measuring 62 mm × 57 mm × 38 mm is being presented here. The patient was advised surgical management by the conventional physician; however, the patient opted for Ayurvedic treatment. A regimen comprising of oral medications including Gandharvahastadi kashaya, Dhanwantara taila, Shigru guggulu , and local application of Lepa (~anointment) of Shigru patra ( Moringa oleifera Lam.) was administered for one month. Follow-up ultrasonography revealed complete resolution of the cyst, with sustained symptomatic relief and no recurrence at seven months. The present case demonstrated complete radiological resolution of a PIC following Ayurvedic intervention without surgery, suggesting a potential conservative management option in selected stable cases. Further clinical studies are needed to establish its efficacy and reproducibility in larger population.

Open article ↗



2026-01-12 | Cytoreductive surgery and HIPEC for multicystic peritoneal mesothelioma: therapeutic approach in a rare benign neoplasm.

Multicystic peritoneal mesothelioma (MCPM) is an uncommon tumor of mesothelial origin, characterized by multiple interconnected cystic spaces and uncertain biological behavior. Although traditionally considered benign, its tendency to recur and occasionally spread within the peritoneal cavity challenges this perception. We describe a 32-year-old woman who experienced gradually worsening pelvic pain and a constant feeling of pressure, which intensified after childbirth. Imaging revealed a large multilocular cystic mass occupying the pelvis. At laparotomy, a gelatinous, multilocular lesion was found adherent to the pelvic peritoneum, uterus, ovaries, and rectosigmoid colon. Complete cytoreductive surgery was performed, including pelvic peritonectomy, omentectomy, appendectomy, and resection of the affected serosa, followed by closed-abdomen hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin (300 mg/m2, 42°C, 90 min). Histopathology confirmed benign multicystic mesothelioma with a mesothelial immunophenotype. The patient recovered well and remains disease-free at 6 months. MCPM requires complete cytoreduction, and HIPEC may help achieve lasting disease control.

Open article ↗



2025-10-28 | Peritoneal inclusion cyst presenting as a rectocele after sacrohysteropexy: A case report.

Peritoneal inclusion cysts (PICs) are mesothelial-lined cystic lesions that usually arise in reproductive-aged women after prior pelvic or abdominal surgery. Their diagnosis is often difficult, as they can mimic ovarian tumors or malignant pelvic masses. There are very few reports of PICs following pelvic reconstructive surgery. This report concerns the case of a 40-year-old nulliparous woman with a history of open sacrohysteropexy for stage IV pelvic organ prolapse who presented with progressive left lower quadrant pain and a vaginal bulge. Imaging revealed a large multilocular retroperitoneal cyst enveloping the left ovary and extending into the rectovaginal septum. Tumor markers were within normal limits. Due to the cyst's proximity to the bowel, ureter, and major vessels, and to avoid mesh erosion, a vaginal surgical approach was selected. Approximately 300 mL of serous fluid was drained, the cyst wall was excised under rectal guidance, and marsupialization was performed to the vaginal mucosa. Histopathology confirmed a benign mesothelial-lined cyst. At one-year follow-up, the patient remained asymptomatic with no recurrence evident on imaging. This is seemingly the first reported case of a retroperitoneal PIC following sacrohysteropexy. The case underscores the diagnostic challenges posed by PICs and highlights the role of individualized, minimally invasive management. Clinicians should maintain a high index of suspicion for PICs when evaluating postoperative pelvic or vaginal masses, particularly when imaging suggests a cystic lesion.

Open article ↗



2025-07-04 | Benign multicystic peritoneal mesothelioma: use of hyperthermic intraperitoneal chemotherapy (HIPEC).

Benign Multicystic Peritoneal Mesothelioma (BMPM) is a rare mesothelial neoplasm, first described in 1979, with an estimated incidence of 1-2 cases per million. It primarily affects women of reproductive age and has been associated with chronic inflammatory processes such as endometriosis or previous surgeries. Due to its clinical and radiological similarity to ovarian neoplasms, it is essential to include gynecological pathology in the differential diagnosis.

Open article ↗



2025-04-28 | Cisplatin + docetaxel improves survival over cisplatin + mitomycin C in hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a retrospective study based on propensity score matching.

Pseudomyxoma peritoneum (PMP) of appendiceal origin poses significant treatment challenges with hyperthermic intraperitoneal chemotherapy (HIPEC) regimens offering viable outcomes. This study aimed to compare the efficacy and safety profiles of two HIPEC regimens: cisplatin + docetaxel (CD) and cisplatin + mitomycin C (CM). PMP patients who underwent cytoreductive surgery (CRS) and HIPEC between January 2008 and December 2023 at our center were retrospectively analyzed. Patients were divided into CD and CM groups and matched for baseline characteristics using propensity score matching (PSM). Clinicopathological data, efficacy, and safety profiles were compared. Univariate and multivariate analyses identified independent prognostic factors, and subgroup analyses further compared the two regimens. After PSM, 104 patients met the inclusion criteria (52 in each group). The median overall survival (mOS) was significantly longer in the CD group (156.3 vs. 60.9 months, p = 0.018), with no significant differences in adverse event severity between groups. Multivariate analysis identified HIPEC regimen, completeness of cytoreduction (CC), and pathological type as independent prognostic factors. Subgroup analysis showed significant mOS benefit for the CD regimen in patients with peritoneal carcinomatosis index (PCI) ≥ 27, CC 2/3, high grade pathology, tumor markers ≥1 evaluated and BMI < 25 (all p < 0.005). Following CRS, the CD regimen offers superior survival benefits compared to the CM regimen for PMP patients. These findings highlight the potential of personalized HIPEC strategies to optimize outcomes for PMP treatment.

Open article ↗



antibodies
2026-05-28 | Simultaneous Occurrence of Well-Differentiated Papillary Mesothelial Tumor and Multicystic Mesothelioma

We report a rare case of simultaneous well-differentiated papillary mesothelial tumor (WDPMT) and multicystic mesothelioma. The concurrent occurrence of these entities is exceptionally uncommon and may pose challenges during surgical intervention. Both tumors are variants of epithelioid mesothelioma and are most frequently identified incidentally during surgical procedures. A 41-year-old patient was admitted for laparoscopic surgery due to a left adnexal mass. Ultrasound examination revealed a 5 cm lesion adjacent to the left ovary, exhibiting central vascularization. Intraoperatively, the mass appeared as a solid, soft, and nodular tumor. Frozen section analysis confirmed the diagnosis of WDPMT involving the left adnexa. Recognition of well-differentiated papillary mesothelial tumor and multicystic mesothelioma is critical for accurate differential diagnosis from malignant mesothelioma. Awareness of these entities informs appropriate surgical management and follow-up protocols.

Open article ↗



2026-02-10 | Incidental Adnexal Lesions: CT Diagnosis and Interreader Agreement.

Background The management of incidental adnexal lesions encountered at CT depends on the diagnosis, but little evidence supports CT diagnosis of most adnexal lesion types. Purpose To evaluate the interreader agreement and CT diagnosis of incidentally discovered adnexal lesions. Materials and Methods This institutional review board-approved, multi-institutional, multireader retrospective study conducted from January 1, 2022, to June 30, 2023, included patients who had malignant ovarian lesions with metastases (n = 8) and without metastases (n = 8), simple cysts (n = 6), dermoids (n = 9), hydrosalpinx (n = 5), benign cystadenomas and/or cystadenofibromas (n = 10), hemorrhagic cysts (n = 8), endometriomas (n = 6), ovarian fibromas (n = 5), leiomyomas (n = 5), and peritoneal inclusion cysts (n = 5) detected at CT. Nine members of the Society of Abdominal Radiology Uterine and Ovarian Cancer Disease-Focused Panel, blinded to the final diagnosis, independently reviewed the CT images and used the American College of Radiology white paper to determine the most likely diagnosis. A 2 × 2 factorial random-effects model was used to calculate the mean adjusted accuracy and disparity among the readers. Interreader agreement was calculated using a Gwet AC1 test. Results In total, 75 patients (mean age, 50 years ± 16 [SD]) were included. The mean adjusted accuracy and interreader agreement were highest for dermoids (99% and 0.97, respectively), malignant ovarian lesions with metastases (94% and 0.90), and simple cysts (86% and 0.64). The mean adjusted accuracy for all other lesion types was less than 72%, with fair to moderate interreader agreement. Overall, readers more accurately diagnosed malignant lesions (82%) than benign lesions (52%) (P < .001). Readers recorded a benign diagnosis when a malignant lesion was present 28% of the time (20 of 72) (P < .001) when there were no metastases. Conclusion Readers' mean adjusted accuracy was greatest for dermoids, malignant ovarian lesions with metastases, and simple cysts at CT, with substantial to almost perfect interreader agreement; all other lesions were challenging, and a substantial number of malignant ovarian lesions were misdiagnosed as benign. © RSNA, 2026.

Open article ↗



2025-07-03 | A large peritoneal inclusion cyst in a postmenopausal female without risk factors.

Peritoneal inclusion cysts (PICs) are rare, benign cystic lesions most often seen in females of reproductive age with a history of peritoneal injury. This case presents a 55-year-old postmenopausal female with no known risk factors who developed a large PIC, causing abdominal pain, fullness, and distention. Imaging, including CT and MRI, revealed a lobulated, fluid-filled mass in the left peritoneal cavity, initially suspected to be a lymphangioma. MRI confirmed the presence of a multilocular cyst with enhancing septa. Surgical exploration identified the cyst as a PIC involving the jejunal mesentery, with final pathology confirming the benign nature of the lesion. While PICs are typically associated with premenopausal females and peritoneal trauma, this case highlights their potential occurrence in postmenopausal age groups without prior insults. The ability to recognize characteristic imaging features-such as cystic lesions with enhancing septa on CT and MRI-can help differentiate PICs from other cystic abdominal masses, including lymphangiomas and neoplastic cystic masses.

Open article ↗



2025-04-12 | Multicystic peritoneal mesothelioma with floret-like multinucleated giant cells: A case report.

Multicystic peritoneal mesothelioma is an uncommon neoplasm characterized by multiple cysts adhering to the abdominal cavity. The symptoms are nonspecific, and their severity appears to be related to the size and location of the cysts. We report the case of a 55-year-old man with morbid obesity in whom a multiloculated mesenteric mass was incidentally discovered on abdominal ultrasound. Complementary imaging studies revealed a multicystic peritoneal tumour with a maximum diameter of 32cm, located in the pelvis and extending to the right hemiabdomen. Histologically, multiple cysts lined by mesothelial cells without atypia were observed, along with loose fibrous stroma containing numerous multinucleated floret-like giant cells. Based on the histopathological findings, the final diagnosis was multicystic peritoneal mesothelioma.

Open article ↗



2022-01-04 | A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial.

Platinum based chemotherapy is the treatment of choice for ovarian cancer patients with a platinum treatment free interval of >6 months. Niraparib is an oral poly (ADP-ribose) polymerase inhibitor approved as maintenance therapy after a response to platinum rechallenge, regardless of BRCA status. Atezolizumab is a humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1). A combination of poly (ADP-ribose) polymerase inhibitor and anti-PD-L1/programmed cell death protein 1 (PD-1) has shown synergy in preclinical models and promising clinical activity. To determine whether the addition of atezolizumab to carboplatin based chemotherapy and to subsequent maintenance with niraparib improves progression free survival compared with placebo in patients with recurrent disease and a platinum treatment free interval of >6 months. The Atezolizumab and NIraparib Treatment Association (ANITA) trial is a GEICO (Grupo Español de Investigación en Cáncer de Ovario) led phase III, randomized, double-blinded, multicenter European Network for Gynecological Oncological Trials (ENGOT) study. Patients will be randomized to arm A (control arm) consisting of platinum based chemotherapy (investigator's choice) plus a placebo of atezolizumab followed by maintenance niraparib plus a placebo of atezolizumab, or to arm B (experimental arm) consisting of platinum based chemotherapy (investigator's choice) plus atezolizumab followed by maintenance niraparib plus atezolizumab. Inclusion criteria are women aged over 18 years, diagnosed with relapsed high grade serous, endometrioid, or undifferentiated ovarian, fallopian tube, or primary peritoneal carcinoma. Patients are eligible if they received no more than two previous lines of chemotherapy, relapsed ≥6 months after the last platinum containing regimen, and have at least one measurable lesion according to the response evaluation criteria in solid tumors, version 1.1. The primary endpoint for this study is progression free survival. Approximately 414 patients will be recruited and randomized in a 1:1 ratio, with the aim of demonstrating a benefit in progression free survival for the experimental arm with a hazard ratio of O.7, using a two sided alpha of 0.05 and a power of 80%. The trial was launched in the fourth quarter of 2018 and is estimated to close in the second quarter of 2021. Mature results for progression free survival are expected to be presented by 2023. Clinicaltrials.gov NCT03598270.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

0 orphan drug designations.

0 orphan drug designations.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.